bisantrene has been researched along with Leukemia P388 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angier, RB; Citarella, RV; Durr, FE; Forbes, M; Murdock, KC; Wallace, RE | 1 |
| Citarella, RV; Durr, FE; Kohlbrenner, M; Lee, VJ; Murdock, KC; Nicolau, G | 1 |
| Alberts, DS; Dorr, RT; Einspahr, J; Milton, S; Remers, WA; Tunget, CL; Wunz, TP | 1 |
3 other study(ies) available for bisantrene and Leukemia P388
| Article | Year |
|---|---|
Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Topics: Animals; Anthracenes; Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Fluorouracil; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Plasmacytoma | 1982 |
N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity.
Topics: Animals; Anthracenes; Antibiotics, Antineoplastic; Leukemia P388; Melanoma, Experimental; Mice; Prodrugs; Rats; Rats, Sprague-Dawley | 1993 |
New antitumor agents containing the anthracene nucleus.
Topics: Animals; Anthracenes; Cell Line; Chemical Phenomena; Chemistry; DNA; Humans; Leukemia L1210; Leukemia P388; Mice; Mitoxantrone; Neoplasms; Protein Biosynthesis; RNA; Structure-Activity Relationship | 1987 |